Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC

By Reck Martin  

Future Oncology, Vol. 2, Iss. 1, 2006-02 ,pp. : 47-51

Future Medicine

Access to resources Recommend Favorite

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

By Rosell Rafael   Taron Miquel   Sanchez Jose Javier   Paz-Ares Luis  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 277-283

Future Medicine

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

By Chen Jianping   Smith Melissa   Kolinsky Kenneth   Adames Violeta   Mehta Nila   Fritzky Luke   Rashed Mohammad   Wheeldon Eric   Linn Michael   Higgins Brian  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 651-659

Springer Publishing Company

Access to resources Recommend Favorite